The new product is a type of intramedullary nail, which is a rod that is inserted into a badly broken bone to keep the fragments together, according to the report.
The FDA clearance means that the agency feels that this device is similar to other products on the market and does not require clinical trials.
Read the Commercial Appeal’s report about NovaLign’s new intramedullary nail.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.